1. Introduction {#sec1}
===============

Bone ingrowth into a prosthetic implant is crucial for the longevity of uncemented total hip arthroplasty (THA). Rapid and sound bone ingrowth can increase implant stability and improve long-term bone-implant fixation. In addition, adequate tissue ingrowth may protect the bone-implant interface against wear particle-induced osteolysis, which further decreases the risk of aseptic loosening \[[@B1]\]. Therefore, how to improve bone-implant fixation is always a topic of great interest for joint surgeons.

Zoledronate (ZOL) is a new-generation intravenous bisphosphonate (BP) with the greatest affinity and longest retention for bone mineral, and it has been largely utilized in the treatment of osteoporosis and metastatic bone disease. It has a well-documented profile of possible side effects, such as initial influenza-like illness which has been documented with the first infusion of BPs. Renal failure has been noted in patients with cancer after repetitive high-dose infusions, and an association between BPs and osteonecrosis of the jaw after tooth extraction has been recorded as well \[[@B2], [@B3]\]. ZOL is traditionally believed to be an antiresorptive agent; however, recent animal studies suggested that it could stimulate bone formation and improve implant mechanical fixation \[[@B4], [@B5]\]. Meanwhile, there are clinical studies revealing that ZOL is associated with decreased early implant migration and reduced peri-implant bone loss \[[@B6], [@B7]\]. Nevertheless, apart from these findings, because of small sample sizes and diverse study protocols of previous researches, the exact cellular and molecular mechanisms governing the improved bone content, structure, and strength, induced by the systemically or locally administered ZOL on implant osseointegration, have no consensus. Thus, a preclinical meta-analysis was performed to investigate the effect of systemically or local administrated ZOL on bone-implant fixation in animal models and to guide the design of evidence-based, large-scale preclinical or clinical trials.

2. Materials and Methods {#sec2}
========================

2.1. Inclusion and Exclusion Criteria {#sec2.1}
-------------------------------------

Inclusion criteria for the literature were as follows: (1) original animal studies, (2) studies that aimed to explore the role of ZOL delivery in implant osseointegration, (3) studies that included a control group, which received placebo or no drug, and (4) studies with the outcomes that included pertinent information regarding bone ingrowth, such as bone-to-implant contact (BIC), bone volume/total volume (BV/TV), and bone area. Exclusion criteria were as follows: (1) clinical studies, (2) implants embedded in the mandible or maxilla, and (3) presence of other confounding factors, such as wear debris in a local environment.

2.2. Search Strategy {#sec2.2}
--------------------

Literature, which was published before September 30, 2018, was searched by using the electronic databases MEDLINE, Embase, and EBSCO. No language restriction was applied. The adopted search keywords were "implant AND (bisphosphonates OR zoledronate) AND osseointegration AND arthroplasty." Titles and abstracts of studies that fulfill the eligibility criteria were screened by the authors and checked for agreement. Finally, the reference lists of all full-text papers, which were identified pertinent to the study, were reviewed for any unidentified studies.

2.3. Study Selection {#sec2.3}
--------------------

Two authors (Yao He and Zhengyun Li) independently applied the search strategy to select references from the aforementioned databases. The titles and abstracts were reviewed independently. When in doubt, the full-text articles were retrieved for further examination. These two authors independently assessed each full report to evaluate fulfillment of the inclusion criteria, and corresponding authors were contacted for more information and clarification regarding their data, if necessary. Any disagreement was discussed with the senior author, and when consensus could not be established, that study was excluded.

2.4. Quality Assessment {#sec2.4}
-----------------------

The methodological quality of included studies was assessed independently by two authors (Yao He and Xiang-Dong Wu) according to the ARRIVE guidelines which included title, abstract, background, objectives, ethical statement, study design, experimental procedures, experimental animals, housing and husbandry, sample size, allocation of animals to experimental groups, experimental outcomes, statistical methods, baseline data, numbers analyzed, outcomes and estimation, adverse events, interpretation/scientific implications, generalizability/translation, and funding. Each study was given a quality score out of a possible total of 20 points. Any disagreement was resolved by the senior author (Yao He).

2.5. Data Extraction {#sec2.5}
--------------------

A data extraction form was designed and agreed by the authors, and a pilot test of five articles was performed to ensure their consistency. Initially, two authors (Yao He and Xiang-Dong Wu) independently extracted the data, which were later reviewed jointly to produce the agreed accurate data. Disagreements were resolved by consensus or consultation with the senior author. The extracted data included study design, animal species, implantation site, implant characteristics (material, shape, and coating), ZOL route and dosage, follow-up time, and outcome measurements (BIC, BV/TV, and bone area). In all studies, BIC was calculated as the length percentage of the direct bone-implant interface to the total implant surface, BV/TV was defined as the percentage of mineralized bone volume to total bone tissue volume in the peri-implant region, and bone area was evaluated as the percentage of bone tissue area to the total area of the bone and implant.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Review Manager (RevMan version 5.0, The Cochrane Collaboration in 2008) was used to analyze the included studies. The primary outcome was the BIC between treatment and control groups. From a clinical point of view, the authors (Yao He and Xiang-Dong Wu) performed subgroup analyses according to the animal model (osteoporotic or normal), animal species, and drug dosage and frequency, as well as follow-up time. In case of multiple treatment groups next to a control group within one trial, the animal number in the control group was divided equally by the number of treatment groups. For each arm in a particular study, continuous data were expressed as means and standard deviations (SDs), and dichotomous data were expressed as proportions or risks. For continuous outcomes, we calculated the mean differences (MDs) with 95% confidence interval (CI). For dichotomous outcomes, we estimated the relative risks\' 95% CI. Statistical heterogeneity was assessed by using the value of *I*^2^ and the result of the chi-square test. An *I*^2^ value \>50% suggests statistical heterogeneity, which prompts a random-effects modeling estimate. Otherwise, a fixed-effects approach was used. A *P* value \<0.05 was determined as statistically significant.

3. Results {#sec3}
==========

3.1. Included Studies {#sec3.1}
---------------------

A total of 182 articles were searched from multiple electronic databases. After screening their titles and available abstracts, 20 satisfied the eligibility criteria and were included in the meta-analysis \[[@B8]--[@B27]\] ([Figure 1](#fig1){ref-type="fig"}).

3.2. Characteristics of Enrolled Studies {#sec3.2}
----------------------------------------

The sample size ranged from 10 to 64. In twelve studies, rats were used as animal models; in other seven studies, rabbits were utilized as animal models; and in the last one study, dogs were used as animal models. The follow-up time ranged from 10 days to 1 year. The tail vertebra was used as the implantation site in one study; in another four studies, the femoral condyle was operated on; the remaining 15 studies all selected the proximal tibia as the surgical site. Out of 20 studies, one used the tantalum as the implant, another used the calcium phosphate bone cement, and the remaining eighteen studies used the titanium implant ([Table 1](#tab1){ref-type="table"}).

3.3. Methodological Quality {#sec3.3}
---------------------------

The mean quality score was 18/20 for all of the 20 studies ([Table 2](#tab2){ref-type="table"}) (*κ* = 0.9). Among all publications, eighteen (90%) reported the animal breeding condition, fourteen (70%) reported random allocation, no study reported blinded surgical implantation, and only one (5%) reported blinded outcome assessment. One study (5%) reported sample size calculation.

4. Systemic Administration {#sec4}
==========================

4.1. Bone-to-Implant Contact {#sec4.1}
----------------------------

Ten articles \[[@B8]--[@B17]\] with 193 animals reported BIC measurements with substantial heterogeneity between studies (*I*^2^ = 98%, *P* \< 0.001); thus, the random-effects model was used to evaluate the results. A significant difference of BIC could be found between the treatment and control groups (MD, 13.44; 95% CI, 7.34--19.55; *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}).

Subgroup analyses were performed according to the animal model (osteoporotic *vs.* normal), animal species (rats *vs.* rabbits), ZOL dosage (\>0.1 mg/kg *vs.* \<0.1 mg/kg), administration frequency (single *vs.* multiple), and follow-up time (\>8 weeks *vs.* \<8 weeks). As shown in [Figure 3](#fig3){ref-type="fig"}, ZOL could significantly increase BIC in osteoporotic animals (mean difference, 16.52; 95% CI, 8.07--24.98; *P*=0.0001); however, this effect was not obvious in normal animals (MD, 6.70; 95% CI, −1.75 to 15.15; *P*=0.12). Based on animal species, similar effects of ZOL on BIC were observed for both rats (MD, 12.61; 95% CI, 5.50--19.72; *P*=0.0005) and rabbits (MD, 13.89; 95% CI, 5.80--21.98; *P*=0.0008).

Regarding the drug dosage, when ZOL dosage exceeded 0.1 mg/kg, BIC could be significantly improved compared with the control group (MD, 14.86; 95% CI, 8.20--21.51; *P* \< 0.001) ([Figure 4](#fig4){ref-type="fig"}). On the contrary, administration frequency had no significant impact on BIC (test for subgroup difference: *P*=0.86). Finally, although positive influence of ZOL on BIC has been demonstrated in short follow-up time studies (\<8 weeks; MD, 3.92; 95% CI, 0.69--7.14; *P*=0.02), this effect was much more significant in case of longer follow-up time (\>8 weeks; MD, 17.65; 95% CI, 9.30--26.06; *P* \< 0.001).

4.2. Bone Volume/Total Volume {#sec4.2}
-----------------------------

The pooled analysis of five experiments \[[@B11], [@B13], [@B15], [@B18], [@B19]\] showed a significant difference of BV/TV between ZOL-treated and control groups (MD, 26.28; 95% CI, 7.58--44.99; *P*=0.006) with heterogeneity (*I*^2^ = 99%, *P* \< 0.001) ([Figure 5](#fig5){ref-type="fig"}).

Animal model (osteoporotic *vs.* normal) was initially used for subgroup analysis. The results showed that more effects of ZOL were seen improving BV/TV in osteoporotic animals (MD, 22.28; 95% CI, 11.98--32.58; *P*=0.0004). With regard to animal species, ZOL significantly increased BV/TV in rats (MD, 18.60; 95% CI, 4.59--32.60; *P*=0.009) and rabbits (MD, 8.00; 95% CI, 3.47--12.53; *P*=0.0005). Finally, similar effects of ZOL on bone area were observed for follow-up time \<8 weeks (MD, 13.19; 95% CI, 1.22--25.17; *P*=0.03) and \>8 weeks (MD, 20.12; 95% CI, 6.81--33.43; *P*=0.003). ZOL has a significant effect on BV/TV if ZOL dosage was more than 0.1 mg/kg (MD, 32.85; 95% CI, 20.15 to 45.55; *P* \< 0.001) or if ZOL was given in multiple doses (MD, 28.52; 95% CI, 14.66 to 42.39; *P* \< 0.001).

Animal model (osteoporotic *vs.* normal) was initially used for subgroup analysis. The results showed that ZOL could only improve BV/TV in osteoporotic animals (MD, 30.43; 95% CI, 16.05--44.80; *P* \< 0.001), but not in normal ones (MD, 20.00; 95% CI, −22.18 to 62.19; *P*=0.35). With regard to animal species, ZOL significantly increased BV/TV in rats (MD, 44.75; 95% CI, 37.48--52.01; *P* \< 0.001); however, this effect was not evidenced in rabbits (MD, 15.29; 95% CI, −7.01 to 37.59; *P*=0.18). Finally, ZOL has an effect on BV/TV if ZOL dosage was more than 0.1 mg/kg (MD, 32.85; 95% CI, 20.15--45.55; *P* \< 0.001) and if ZOL was given in multiple doses (MD, 28.52; 95% CI, 14.66--42.39; *P* \< 0.001).

4.3. Bone Area {#sec4.3}
--------------

Only two studies \[[@B9], [@B10]\] with 68 animals reported bone area, and no heterogeneity was observed (*I*^2^ = 0, *P*=0.87) ([Figure 6](#fig6){ref-type="fig"}).

5. Local Administration {#sec5}
=======================

5.1. Bone-to-Implant Contact {#sec5.1}
----------------------------

Seven articles \[[@B20]--[@B25]\] with 117 animals reported BIC measurements with substantial heterogeneity between studies (*I*^2^ = 95%, *P* \< 0.001); thus, the random-effects model was used to evaluate the results. A significant difference of BIC could be found between the treatment and control groups (MD, 13.54; 95% CI, 4.43--22.65; *P*=0.004) ([Figure 2](#fig2){ref-type="fig"}).

Subgroup analyses were performed according to the animal model (osteoporotic *vs.* normal), animal species (rats *vs.* rabbits *vs.* dogs), and follow-up time (\>8 weeks *vs.* \<8 weeks). As shown in [Figure 7](#fig7){ref-type="fig"}, ZOL with local administration could significantly increase BIC in osteoporotic animals (MD, 18.96; 95% CI, 10.27--27.65; *P* \< 0.0001); but in normal animals, there was no effect at all (MD, −0.9; 95% CI, −11.22 to 9.42; *P*=0.86).

Based on animal species, similar effects of ZOL on BIC were observed for rats (MD, 15.16; 95% CI, 0.66--29.66; *P*=0.04) and rabbits (MD, 10.46; 95% CI, 2.21--18.70; *P*=0.01). On the contrary, only the longer follow-up time has a increased effect on BIC (MD, 17.05; 95% CI, 7.21--26.89; *P* \< 0.0007).

5.2. Bone Volume/Total Volume {#sec5.2}
-----------------------------

Only three studies \[[@B15], [@B23], [@B25]\] with 51 animals reported bone volume/total volume with heterogeneity between studies (*I*^2^ = 49%, *P*=0.14) ([Figure 4](#fig4){ref-type="fig"}).

5.3. Bone Area {#sec5.3}
--------------

A total of seven articles \[[@B21]--[@B24], [@B26], [@B27]\] with 125 animals reported bone area showing a significant difference between ZOL-treated and no ZOL groups (MD, 16.02; 95% CI, 5.98--26.05; *P*=0.002) with heterogeneity (*I*^2^ = 97%, *P* \< 0.001) ([Figure 6](#fig6){ref-type="fig"}).

6. Discussion {#sec6}
=============

THA is an effective technique owing to its ability to reduce pain, correct deformity, and improve function. However, its longevity is always an unsolved issue. According to previous reports, the most common reason of implant failure is aseptic loosening, which is caused by implant micromotion, prosthesis-related stress shielding, disuse osteoporosis, and wear-debris-induced osteolysis \[[@B6]\]. Thus, a simple, low-cost, and readily available method for improving implant fixation and decreasing periprosthetic bone loss is considerably important. Over the recent years, some animal study data proposed that ZOL might increase peri-implant bone stock and improve biological implant fixation, whereas other studies have denied this effect \[[@B14]\]. By pooling the currently available animal study data, the present meta-analysis provides evidence-based information about the positive effects of ZOL on implant osseointegration. In addition, our results indicated that the animal model, drug dosage, and follow-up time might influence study outcomes, which suggests possible reasons for the diversity of previous studies and gives insights into the design of future research.

Although bisphosphonates are well-known osteoclast inhibitors, they could reduce bone resorption by inhibiting and promoting apoptosis of osteoclasts \[[@B28], [@B29]\]. Several in vitro studies have demonstrated that they could also stimulate osteoblast function \[[@B30], [@B31]\]. However, according to our results, ZOL could only significantly improve implant osseointegration in osteoporotic animals but not in normal ones, which indicates that this effect was mediated mainly by decreasing the abnormal bone turnover rate rather than directly stimulating bone formation. Meanwhile, caution should be taken when interpreting this result. In the experimental animals, osteoporosis was acquired mainly by ovariectomy and was the only systemic condition. Nevertheless, in clinical settings, osteoporotic patients are usually old aged and sometimes diabetic. It has already been reported that aging and chronic hyperglycemia would lead to accumulation of advanced glycation end products (AGEs), which could negatively influence bone metabolism, and thus, the effect of ZOL may be less promising in clinical settings than in laboratories \[[@B32], [@B33]\].

In view of the widespread use of bisphosphonates and the increase in bisphosphonate-related cases of osteonecrosis of the jaw, some studies have shown that osteonecrosis with dental implants may be a side effect of treatment with BP. The incidence of bisphosphonate-related osteonecrosis of the jaws is accelerated at the end of or during BP treatment. Serra et al. \[[@B34]\] suggested the avoidance of dental implant procedures in patients that have been receiving intravenous BPs. A recent review indicates that one hundred percent of the studies related to combined use of BPs have shown cases of osteonecrosis \[[@B35]\]. Others authors \[[@B36]--[@B41]\] suggested that bisphosphonate exposure and implant placement do not affect implant success and do not result in osteonecrosis. However, the duration of their follow-up was short. Najeeb et al. \[[@B42]\] believe that these results should be confirmed by more in-depth research before the dental implant can be used in the clinic. This is also the reason that one of the exclusion criteria is the implants embedded in the mandible or maxilla in our study.

Rats are the most commonly used animal model for osteoporosis studies because the ovariectomized rat exhibits most of the characteristics of human postmenopausal osteoporosis. However, the lack of intracortical remodeling process in this animal compromises the physiologic investigation of the cortical bone. By contrast, rabbits do have some inherent advantages as the osteoporosis animal model. For example, they achieve skeletal maturity shortly after reaching complete sexual development and show significant intracortical remodeling \[[@B43]\]. Thus, some researchers prefer rabbits as their ideal model. With respect to our results, studies with rats or rabbits have achieved similar yet slightly different outcomes, indicating that different animal models may influence implant osseointegration characteristics. However, because of the limited number of included studies, drawing the final conclusion now is too early.

The dosage and frequency of ZOL delivery varied among the included studies, and the best medication administration protocol remains unclear. According to the present study, administration frequency does not exert much influence as long as drug dosage exceeds 0.1 mg/kg. This information is quite important because concerns about the safety of long-term bisphosphonate usage are always present. If single and multiple administrations have similar osseointegration-improving effects, long-term usage would be unnecessary, thus avoiding the risk of complications, such as osteonecrosis of the jaw or stress fracture \[[@B44]\].

This meta-analysis has several limitations. Firstly, because of the small number of included studies and the limited animal sample sizes, conclusions from this meta-analysis should be interpreted cautiously and should be substantiated by larger studies. Secondly, because of the diverse study characteristics, animal populations, and treatment protocols, significant heterogeneity existed among the included studies. Nevertheless, because the main focus of preclinical meta-analysis is to generate hypotheses, the existence of heterogeneity is quite rational and could provide insight into the design of future clinical trials \[[@B45]\].

7. Conclusions {#sec7}
==============

In conclusion, current animal studies demonstrate that both systemic and local administration of ZOL could improve the osseointegration of the orthopedic implant in animal models. An appropriate animal model (osteoporotic), sufficient drug dosage (exceeding 0.1 mg/kg, only in the method of systemic administration), and enough follow-up time (more than eight weeks) are crucial influencing factors, which should be given particular attention in future animal or clinical studies. Nonetheless, caution should be taken when interpreting the results of this meta-analysis because of inherent differences between preclinical and clinical subjects.

Additional Points
=================

*Strengths and Limitations of This Study*. (1) Both systemic and local administration of ZOL could improve the osseointegration of the orthopedic implant in animal models. (2) The osteoporotic model could be more effective to improve the osseointegration of the orthopedic implant than the normal model. (3) Sufficient drug dosage (exceeding 0.1 mg/kg, only the method of systemic administration) and enough follow-up time (more than eight weeks) are crucial influencing factors. (4) This meta-analysis should be considered cautiously and should be substantiated by larger studies. (5) Results of this meta-analysis should be interpreted cautiously because of the inherent differences between preclinical and clinical subjects.
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###### 

Characteristics of enrolled studies.

  Studies                         Animals          Group              ZOL dosage and route, or concentration   Implant            FU time                                                                  
  ------------------------------- ---------------- ------------------ ---------------------------------------- ------------------ --------------- ------------------------------- ------------------------ ----------
  Ayan et al. \[[@B8]\]           Male rabbits     1: control         9                                        0.1 mg/kg IV       Tibia           Titanium screw                  No                       4 weeks
  2: ZOL                          Single dose                                                                                                                                                              
                                                                                                                                                                                                           
  Cardemil et al. \[[@B9]\]       Female rats      1: control (OVX)   28                                       0.1 mg/kg IV       Tibia           Titanium screw                  No                       4 weeks
  2: ZOL                          Single dose                                                                                                                                                              
                                                                                                                                                                                                           
  Carvas et al. \[[@B10]\]        Male rabbits     1: control (GC)    6                                        0.1 mg/kg IV       Tibia           Titanium screw                  No                       18 weeks
  2: ZOL                          Single dose                                                                                                                                                              
                                                                                                                                                                                                           
  Chen et al. \[[@B11]\]          Female rats      1: control (OVX)   12                                       0.1 mg/kg IV       Tibia           Titanium rod                    HA                       12 weeks
  2: ALN                          Single dose                                                                                                                                                              
  3: SR                                                                                                                                                                                                    
  4: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Dikicier et al. \[[@B12]\]      Female rats      1: control (OVX)   12                                       0.04 mg/kg IV      Tibia           Titanium screw                  No                       8 weeks
  2: ZOL                          6 doses                                                                                                                                                                  
                                                                                                                                                                                                           
  Li et al. \[[@B13]\]            Female rabbits   1: control (OVX)   6                                        0.1 mg/kg SC       Tibia           Titanium screw                  HA                       8 weeks
  2: ZOL                          3 doses                                                                                                                                                                  
                                                                                                                                                                                                           
  de Oliveira et al. \[[@B14]\]   Male rats        1: control         3                                        0.0075 mg/kg SC    Tibia           Titanium                        No                       4 weeks
  2: ZOL                          3 doses                                                                                                                                                                  
                                                                                                                                                                                                           
  Qi et al. \[[@B15]\]            Female rabbits   1: control (OVX)   8                                        0.1 mg/kg SC       Tibia           Titanium screw                  HA                       12 weeks
  2: local ZOL                    4 doses                                                                                                                                                                  
  3: systemic ZOL                                                                                                                                                                                          
  4: local and systemic ZOL                                                                                                                                                                                
                                                                                                                                                                                                           
  Yaman et al. \[[@B16]\]         Male rats        1: control         7                                        0.1 mg/kg IV       Tibia           Titanium screw                  HA                       12 weeks
  2: ZOL                          3 doses                                                                                                                                                                  
                                                                                                                                                                                                           
  Yildiz et al. \[[@B17]\]        Female rabbits   1: control (OVX)   12                                       0.1 mg/kg IV       Tibia           Titanium screw                  Resorbable blast media   8 weeks
  2: ZOL                          Single dose                                                                                                                                                              
                                                                                                                                                                                                           
  Blazsek et al. \[[@B18]\]       Female rats      1: control         5                                        0.6 mg/kg IP       Tail vertebra   Titanium screw                  No                       6 weeks
  2: ZOL                          3 doses                                                                                                                                                                  
                                                                                                                                                                                                           
  von Knoch et al. \[[@B19]\]     Rabbits          1: control         12                                       0.015 mg/kg IV     Femur           Titanium cylinder               Fiber metal mesh         12 weeks
  2: ZOL                          Single dose                                                                                                                                                              
                                                                                                                                                                                                           
  Arnoldi et al. \[[@B20]\]       Rabbits          1: control         6                                        1 *μ*g/ml          Femur           Titanium screw                  No                       10 days
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Miettinen et al. \[[@B21]\]     Male rats        1: control         7                                        20 *μ*g/ml         Femur           Titanium                        No                       4 weeks
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Gao et al. \[[@B22]\]           Female rats      1: control (OVX)   10                                       1 mg/ml            Tibia           Titanium                        HA                       12 weeks
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Stadlinger et al. \[[@B23]\]    Female rats      1: control (OVX)   8                                        8.5 *μ*g/implant   Tibia           Titanium                        No                       4 weeks
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Ying et al. \[[@B24]\]          Female rats      1: control (OVX)   10                                       30 *μ*g/implant    Tibia           Titanium cylinder               No                       12 weeks
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Pyo et al. \[[@B25]\]           Female rats      1: control (OVX)   10                                       8 *μ*g/ml          Tibia           Titanium screw                  No                       8 weeks
  2: ZOL                          80 *μ*g/ml                                                                                                                                                               
                                  800 *μ*g/ml                                                                                                                                                              
                                                                                                                                                                                                           
  Sörensen et al. \[[@B26]\]      Rats             1: control         10                                       50 *μ*g/implant    Tibia           Calcium phosphate bone cement   No                       3 weeks
  2: ZOL                                                                                                                                                                                                   
                                                                                                                                                                                                           
  Bobyn et al. \[[@B27]\]         Dogs             1: control         5                                        0.2 mg/ml          Femur           Tantalum                        HA                       1 year
  2: ZOL                                                                                                                                                                                                   

ZOL: zoledronate; FU: follow-up; GC: glucocorticoid; HA: hydroxyapatite; ALN: alendronate; SR: strontium ranelate; SC: subcutaneous; IP: intraperitoneal.

###### 

Quality assessment score of enrolled studies.

  Studies                        Quality score
  ------------------------------ ---------------
  Ayan et al. \[[@B8]\]          18
  Cardemil et al. \[[@B9]\]      17
  Carvas et al. \[[@B10]\]       16
  Chen et al. \[[@B11]\]         19
  Dikicier et al. \[[@B12]\]     17
  Li et al. \[[@B13]\]           17
  Marcio et al. \[[@B14]\]       19
  Qi et al. \[[@B15]\]           17
  Yaman et al. \[[@B16]\]        19
  Yildiz et al. \[[@B17]\]       18
  Blazsek et al. \[[@B18]\]      17
  von Knoch et al. \[[@B19]\]    18
  Arnoldi et al. \[[@B20]\]      18
  Miettinen et al. \[[@B21]\]    18
  Gao et al. \[[@B22]\]          19
  Stadlinger et al. \[[@B23]\]   19
  Ying et al. \[[@B24]\]         19
  Pyo et al. \[[@B25]\]          19
  Sörensen et al. \[[@B26]\]     18
  Bobyn et al. \[[@B27]\]        17
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